Hiya Bonker, and the BB, , Im still in this (albiet sitting on quite a big paper loss at the moment) I dont post much on here because its all way above me the med stuff, I have a personal reason as well as a share reason for jumping aboard, thats when it was around the .90 level, ok so this new publication everyone is banging on about, is this test results coming through? and if so what are the LTH,s here expecting to hapen from here on in timescale wise?, sorry for asking these questions its just that my PF is full of oilys and mining, I got caught out on the spike a while ago and came in at 1.2 but stupidy set a stop loss that kicked in, anyway, like I say, I am back in so hopefully Its about to start heading north, GLA
I'll be the first to admit I find a lot of the science stuff heavy reading. Suppose you could say I'm largely ignorant in that respect which many would view as a hindrance but I suppose the flip side is it means I don't base opinions in the same way as if I did have a background in medicinal science?
Oh, did you see The Chase earlier? Thoth was the answer to one of the questions. Made me chuckle anyway.
So to sum up, it's all good then (understatement, ha ha)!. Cells treated with CCT244747, Paclitaxel and radiation triple therapy undergo mitotic catastrophe. I like the sound of Mitotic Catastrophe, it's got a certain ring of finality for the cancer cells to it. A massive ray of hope. Well done Thoth and everyone else tonight. Great stuff. Night time is certainly the right time on here.
Cruk crt etc pursuing a personalised combination strategy. Using off patent drugs in combination with our chk1 inhibitor. Giving better results than opdiva or keytruda in the same indications. They are $5bn each compounds. End august I'll be hat eating if not bought by then......
The full article is complicated, but they have outlined an effective schedule for our CHK1 inhibitor and it is labelled by them as "highly selective, potent, orally administered inhibitor" and the results are darn good.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.